What is the approximate health insurance price of enzalutamide/enzalutamide in 2025?

Enzalutamide/Enzalutamide ( Enzalutamide) is an oral targeted drug for prostate cancer widely used around the world. Its core mechanism is to fundamentally cut off the tumor-dependent endocrine pathway by blocking the activation and signal transduction of androgen receptors. Its advent has changed the long-term dependence on chemotherapy for patients with advanced prostate cancer, making it possible for oral drugs to prolong survival and improve quality of life. Today, enzalutamide is considered an important treatment option in first or second line for both metastatic castration-resistant prostate cancer and castration-sensitive disease stages.

In China, enzalutamide has been launched on the market and entered the medical insurance directory, and is included in the category B reimbursement. Based on the current common specifications of 40mg*112 capsules, the market retail price of each box is approximately more than 5,000 yuan, and the actual out-of-pocket proportion of patients will significantly decrease after medical insurance reimbursement. The reimbursement ratio may vary in different regions, generally fluctuating between 60% and 80%. In other words, the monthly medication cost for patients may be reduced from the original high tens of thousands of yuan to a few thousand yuan, which greatly improves the accessibility of drugs.

With the dynamic adjustment of the national negotiation mechanism and competition for similar drugs entering the market, the price of enzalutamide may still decline in the future. At the time point of 2025, the medical insurance price will still remain at about 5,000 yuan per box, but the actual expenditure of patients will be further reduced based on medical insurance coverage and reimbursement ratio. For prostate cancer patients undergoing long-term treatment, this policy optimization has greatly reduced the economic pressure, making oral targeted drugs truly popular and routine.

Therefore, from an application perspective, enzalutamide not only has stable clinical efficacy and long-term value, but with the support of medical insurance policies, it has also become an affordable and long-term treatment option for prostate cancer patients.

Reference materials:https://www.xtandi.com/